drugset / Trial / NCT06671509
Pharmacokinetics and Safety Study of YZJ-1139 in Subjects With Mild, Moderate and Normal Hepatic Impairment
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Primary Objectives: To evaluate the effect of the subjects with mild (Child Pugh A), moderate (Child Pugh B) and normal hepatic impairment on the pharmacokinetics of YZJ-1139 Secondary Objectives: To evaluate the safety of a single oral dose of YZJ-1139 in subjects with mild, moderate and normal hepatic impairment
Timeline
- Start
- 2024-03-22
- Primary completion
- 2024-04-18
- Completion
- 2024-08-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FAZAMOREXANT | Small molecule | 20 mg | Oral |